Rituximab – USA

Rituximab – USA

IPR decision (Feb. 21, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01614
08/15/2016
Celltrion, Inc.
Apotex Inc.
US 7,820,161
claims 1–12 are patentable
On US’161 patent, Celltrion previously filed IPR (IPR2015-01744) which was denied.  Boehringer Ingelheim filed IPR (IPR2015-00415) which was terminated (Oct 2015) as BI filed “Request for Adverse Judgment”. Pfizer also filed IPR (IPR2017-01115) on 03/24/2017 which was instituted on 07/18/2017.
US 7,820,161 (Genentech / Biogen; Exp: May 04, 2020)
1. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and (b) administering to the human methotrexate.
5. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the CD20 antibody administration consists of intravenous administration of the CD20 antibody, and the CD20 antibody is rituximab.

9. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the therapeutically effective amount of the CD20 antibody is administered intravenously, and the CD20 antibody is rituximab.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved